PP
GSK icon

Palladium Partners’s GSK GSK Stock Holding History

Palladium Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,128
Closed -$210K – 246
2020
Q2 		$210K Buy
+4,128
New +$212K 0.01% 237
2020
Q1 		– Sell
-4,128
Closed -$242K – 249
2019
Q4 		$242K Sell
4,128
-1,342
-25% -$74.6K 0.02% 243
2019
Q3 		$275K Buy
5,470
+1,009
+23% +$51.9K 0.02% 226
2019
Q2 		$223K Sell
4,461
-160
-3% -$8.03K 0.02% 253
2019
Q1 		$241K Sell
4,621
-1,129
-20% -$56.4K 0.02% 238
2018
Q4 		$275K Sell
5,750
-625
-10% -$30.8K 0.02% 215
2018
Q3 		$320K Sell
6,375
-91
-1% -$4.62K 0.02% 230
2018
Q2 		$326K Buy
6,466
+905
+16% +$45.6K 0.02% 226
2018
Q1 		$272K Hold
5,561
– – 0.02% 237
2017
Q4 		$247K Sell
5,561
-226
-4% -$10.4K 0.02% 242
2017
Q3 		$294K Buy
5,787
+146
+3% +$7.41K 0.02% 224
2017
Q2 		$304K Sell
5,641
-1,600
-22% -$85.3K 0.02% 216
2017
Q1 		$382K Buy
7,241
+1,430
+25% +$72.5K 0.03% 205
2016
Q4 		$280K Sell
5,811
-200
-3% -$9.88K 0.02% 216
2016
Q3 		$324K Buy
6,011
+1,110
+23% +$60.9K 0.03% 206
2016
Q2 		$266K Buy
4,901
+364
+8% +$19.2K 0.02% 215
2016
Q1 		$230K Sell
4,537
-800
-15% -$39.8K 0.02% 216
2015
Q4 		$269K Sell
5,337
-160
-3% -$8.15K 0.02% 210
2015
Q3 		$264K Sell
5,497
-1,800
-25% -$93.7K 0.03% 204
2015
Q2 		$380K Sell
7,297
-308
-4% -$17.3K 0.03% 204
2015
Q1 		$439K Sell
7,605
-120
-2% -$6.88K 0.04% 202
2014
Q4 		$413K Buy
7,725
+1,569
+25% +$87.8K 0.04% 206
2014
Q3 		$354K Sell
6,156
-89
-1% -$5.46K 0.03% 206
2014
Q2 		$417K Sell
6,245
-1,440
-19% -$97.5K 0.04% 199
2014
Q1 		$513K Hold
7,685
– – 0.05% 192
2013
Q4 		$513K Hold
7,685
– – 0.05% 194
2013
Q3 		$482K Hold
7,685
– – 0.05% 191
2013
Q2 		$480K Buy
+7,685
New +$488K 0.05% 190

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Palladium Partners's GSK Position: Q3 2020 in Review

Palladium Partners sold out of GSK (GSK) in Q3 2020, closing a stake of 4,128 shares — an estimated $210K sold.

Palladium Partners first reported a position in GSK in Q2 2013 and held it in 28 quarters. The position peaked at $513K in Q1 2014. 826 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

  • Palladium Partners reported no remaining GSK position as of Q3 2020 after selling out during the quarter.
  • Palladium Partners sold 4,128 GSK shares in Q3 2020, an estimated $210K.
  • Palladium Partners first reported a position in GSK in Q2 2013 and held it in 28 quarters.
  • Palladium Partners's GSK position peaked at $513K in Q1 2014.
  • 826 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on Palladium Partners's 13F filing for Q3 2020, filed 6 Nov 2020.